Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder.
BACKGROUND
Reports of reduced pain sensitivity in autism have prompted opioid theories of autism and have practical care ramifications. Our objective was to examine behavioral and physiological pain responses, plasma beta-endorphin levels and their relationship in a large group of individuals with autism.


RESULTS
The study was conducted on 73 children and adolescents with autism and 115 normal individuals matched for age, sex and pubertal stage. Behavioral pain reactivity of individuals with autism was assessed in three observational situations (parents at home, two caregivers at day-care, a nurse and child psychiatrist during blood drawing), and compared to controls during venepuncture. Plasma beta-endorphin concentrations were measured by radioimmunoassay. A high proportion of individuals with autism displayed absent or reduced behavioral pain reactivity at home (68.6%), at day-care (34.2%) and during venepuncture (55.6%). Despite their high rate of absent behavioral pain reactivity during venepuncture (41.3 vs. 8.7% of controls, P<0.0001), individuals with autism displayed a significantly increased heart rate in response to venepuncture (P<0.05). Moreover, this response (Delta heart rate) was significantly greater than for controls (mean+/-SEM; 6.4+/-2.5 vs. 1.3+/-0.8 beats/min, P<0.05). Plasma beta-endorphin levels were higher in the autistic group (P<0.001) and were positively associated with autism severity (P<0.001) and heart rate before or after venepuncture (P<0.05), but not with behavioral pain reactivity.


CONCLUSIONS
The greater heart rate response to venepuncture and the elevated plasma beta-endorphin found in individuals with autism reflect enhanced physiological and biological stress responses that are dissociated from observable emotional and behavioral reactions. The results suggest strongly that prior reports of reduced pain sensitivity in autism are related to a different mode of pain expression rather than to an insensitivity or endogenous analgesia, and do not support opioid theories of autism. Clinical care practice and hypotheses regarding underlying mechanisms need to assume that children with autism are sensitive to pain.
Tordjman
Sylvie
S
Laboratoire Psychologie de la Perception, Université Paris Descartes, UMR 8158 CNRS, Paris, France. s.tordjman@ch-guillaumeregnier.fr
Anderson
George M
GM
Botbol
Michel
M
Brailly-Tabard
Sylvie
S
Perez-Diaz
Fernando
F
Graignic
Rozenn
R
Carlier
Michèle
M
Schmit
Gérard
G
Rolland
Anne-Catherine
AC
Bonnot
Olivier
O
Trabado
Séverine
S
Roubertoux
Pierre
P
Bronsard
Guillaume
G
D000293:Adolescent; D001321:Autistic Disorder / Q000097:blood / Q000503:physiopathology*; D016022:Case-Control Studies; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D010146:Pain / Q000503:physiopathology*; D001615:beta-Endorphin / Q000097:blood*
D001615:beta-Endorphin
Psychiatry Res. 1992 Feb;41(2):179-86
1315442
J Dev Behav Pediatr. 1999 Aug;20(4):235-43
10475598
Clin J Pain. 1996 Jun;12(2):135-41
8776553
Psychopharmacol Bull. 1993;29(2):221-7
8290669
J Pers. 1951 Jun;19(4):359-75
14874176
BMJ. 1996 Sep 28;313(7060):796
8842075
Pain. 1992 Jan;48(1):45-52
1738574
Pharmacol Biochem Behav. 1978 Aug;9(2):213-20
568801
Clin Pediatr (Phila). 1976 Dec;15(12):1114-9
991529
J Autism Dev Disord. 1994 Oct;24(5):659-85
7814313
Psychiatry Res. 1995 Oct 16;58(3):191-201
8570775
Am J Ment Defic. 1983 Sep;88(2):177-86
6638079
Dev Med Child Neurol. 1998 May;40(5):340-3
9630262
J Child Psychol Psychiatry. 1997 Sep;38(6):705-15
9315980
Neuroendocrinology. 1992 Sep;56(3):419-28
1331840
J Dev Behav Pediatr. 1999 Aug;20(4):244-52
10475599
Lancet. 1994 Aug 27;344(8922):615
7914981
J Dev Behav Pediatr. 1999 Aug;20(4):228-34
10475597
Psychopharmacology (Berl). 1984;82(4):368-70
6427830
Biol Psychiatry. 1983 Jan;18(1):99-101
6299409
Appl Res Ment Retard. 1983;4(1):5-11
6870234
Clin J Pain. 2009 Mar-Apr;25(3):244-52
19333176
Clin J Pain. 1999 Mar;15(1):13-23
10206563
J Autism Dev Disord. 1991 Mar;21(1):83-7
2037552
J Autism Dev Disord. 1997 Apr;27(2):155-63
9105966
Mol Psychiatry. 2001 Jul;6(4):434-9
11443529
Med Hypotheses. 1997 May;48(5):413-4
9185129
Arch Gen Psychiatry. 1985 Aug;42(8):780-3
4015322
Am J Ment Retard. 1994 Mar;98(5):619-31
8192908
Am J Ment Defic. 1985 Sep;90(2):124-9
2996351
Biol Psychiatry. 1990 Nov 1;28(9):773-93
2175218
Brain Dev. 1990;12(1):88-92
2344033
Psychopharmacol Bull. 1990;26(1):130-5
2196621
Isr J Med Sci. 1990 May;26(5):275-7
2380025
Biol Psychiatry. 1999 Jan 15;45(2):158-63
9951562
J Psychiatr Pract. 2006 Mar;12(2):90-102
16728905
Pain. 2000 Jan;84(1):65-75
10601674
J Autism Child Schizophr. 1978 Dec;8(4):477-9
730668
Clin J Pain. 2004 Mar-Apr;20(2):88-97
14770048
J Am Acad Child Adolesc Psychiatry. 1988 Jul;27(4):430-3
2972691
Neuropsychobiology. 1997;35(1):1-4
9018016
Brain Res Bull. 1978 Nov-Dec;3(6):663-7
318190
Encephale. 1999 Mar-Apr;25(2):122-34
10370885
Cephalalgia. 1999 Oct;19(8):725-7
10570727
Arch Gen Psychiatry. 1995 Sep;52(9):766-73
7654128
J Autism Dev Disord. 1987 Jun;17(2):201-16
3038836
Am J Psychiatry. 1994 Dec;151(12):1797-801
7977888
Pediatr Neurol. 1987 Mar-Apr;3(2):83-6
2977280
J Autism Dev Disord. 1992 Jun;22(2):309-19
1345670
Kurume Med J. 1993;40(4):233-41
8007632
Neuroendocrinology. 1989 Oct;50(4):372-81
2812272
J Psychiatr Res. 1994 Mar-Apr;28(2):109-22
7932274
Life Sci. 1979 Nov 12;25(20):1755-60
575184
J Pediatr Psychol. 2000 Jul-Aug;25(5):301-8
10880060
Eur Neuropsychopharmacol. 1999 Jun;9(4):361-6
10422898